SCHEMBL3014922

SCHEMBL3014922

CC(C)(C)c1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)c(Cl)c4)cs3)CC2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
AR P10275 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GPR183 P32249 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
HSD11B1 P28845 3/20 0.33
NR1I3 Q14994 1/20 0.33
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32
NAMPT P43490 2/20 0.32
DNM1L O00429 1/20 0.32
USP2 O75604 1/20 0.32
EPHX2 P34913 1/20 0.32
ERBB2 P04626 1/20 0.32
EPHA2 P29317 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018140 0.92 PROKR1 (0.34) LMNAL3MBTL1ALDH1A1MAPTHTT
SCHEMBL3015929 0.92 TRPV1 (0.36) LMNAL3MBTL1ALDH1A1MAPTHTT
SCHEMBL3011697 0.90 HSD11B1 (0.39) LMNAALDH1A1MAPTHTTSMN1; SMN2
SCHEMBL3012727 0.90 ALDH1A1 (0.40) LMNAL3MBTL1ARALDH1A1MAPT
SCHEMBL3021340 0.90 MAPT (0.35) LMNAALDH1A1MAPTHTTSMN1; SMN2
SCHEMBL3017923 0.90 MAPT (0.40) LMNAL3MBTL1ARMAPTSMN1; SMN2
SCHEMBL3013801 0.90 L3MBTL1 (0.39) LMNAL3MBTL1ARALDH1A1MAPT
SCHEMBL3016045 0.88 DNM1L (0.34) ALDH1A1MAPTHTTSMN1; SMN2NPSR1
SCHEMBL3014815 0.88 L3MBTL1 (0.41) LMNAL3MBTL1ARALDH1A1MAPT
SCHEMBL3009192 0.88 LMNA (0.37) LMNAL3MBTL1ARALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885L3MBTL1 1847/4885AR 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.